. Author manuscript; available in PMC: 2022 Oct 28.

Published in final edited form as: J Antimicrob Chemother. 2022 Aug 29;77(11):3110–3117. doi: 10.1093/jac/dkac290

Table 3.

Multivariable linear regression for change in modified mini screen score from baseline to week 4, week 12, and week 24 among participants with available estimated dolutegravir AUC_0-24 concentrations

	Multivariable associations Week 4 (n=461)		Multivariable associations Week 12 (n=461)		Multivariable associations Week 24 (n=461)
	Coefficient (95% CI)	p-value	Coefficient (95% CI)	p-value	Coefficient (95% CI)	p-value
Age (per 10 years increase)	-0.214 (-0.528 to 0.100)	0.181	-0.155 (-0.427 to 0.118)	0.265	-0.119 (-0.342 to 0.104)	0.296
Sex
Female	Referent group
Male	0.111 (-0.263 to 0.486)	0.559	0.167 (-0.173 to 0.507)	0.336	0.109 (-0.188 to 0.406)	0.472
Baseline CD4 count (per 50 cells/mm³increase)	-0.045 (-0.104 to 0.015)	0.141	-0.019 (-0.076 to 0.039)	0.521	-0.027 (-0.075 to 0.020)	0.258
Baseline HIV-1 RNA (per 1 log₁₀ increase)	-0.140 (-0.394 to 0.114)	0.280	-0.133 (-0.394 to 0.127)	0.315	-0.115 (-0.324 to 0.094)	0.281
Arm
TAF	Referent group
TDF	-0.161 (-0.537 to 0.216)	0.402	-0.009 (-0.365 to 0.348)	0.962	-0.107 (-0.409 to 0.194)	0.486
DTG AUC_0-24 (mg·h/L) (per 1 log₁₀ increase)	-0.826 (-2.037 to 0.385)	0.181	-1.278 (-2.250 to -0.306)	0.010	-1.145 (-1.953 to -0.338)	0.006

TAF = tenofovir alafenamide, TDF = tenofovir disoproxil fumarate, DTG = dolutegravir, AUC_0-24 = area under the concentration-time curve, PK = pharmacokinetics